title: Response to letter: cilostazol and its emerging benefits in gastroenterology besides its attenuating effect on indomethacin-induced small intestinal injury.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Higashiyama
authors.forename: Ryota
authors.initials: R
authors.lastname: Hokari
authors.forename: Soichiro
authors.initials: S
authors.lastname: Miura
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D007077:Ileal Diseases / Q000517:prevention & control*; D007082:Ileum / Q000187:drug effects* / Q000473:pathology*; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male; D058987:Phosphodiesterase 3 Inhibitors / Q000627:therapeutic use*; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D058987:Phosphodiesterase 3 Inhibitors; D013777:Tetrazoles; D007213:Indomethacin